Biohaven Ltd. Employee-related Liabilities, Current
Biohaven Ltd. (BHVN) had Employee-related Liabilities, Current of $8.23 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Employee-related Liabilities, Current $8.23M.
- 2026-03-31: Employee-related Liabilities, Current $4.43M.
- 2025-12-31: Employee-related Liabilities, Current $16.78M.
- 2025-09-30: Employee-related Liabilities, Current $18.20M.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $8.23M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $4.43M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $16.78M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $18.20M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $12.11M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $6.53M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $154.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $15.88M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $10.85M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.39M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $837.00K 10-Q · filed 2024-11-12 |
| 2023-09-30 | $13.98M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $9.23M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $4.31M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $14.60M 10-K · filed 2024-02-29 |
| 2022-09-30 | $7.54M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $9.54M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |